Introduction
Farnesoid X receptor (FXR; NR1H4), a member of the nuclear hormone receptor superfamily, is highly expressed in major organs including liver, intestine, kidney, and adrenal gland. FXR functions as a ligand-mediated transcription factor by binding to specific DNA motifs in the promoter regions of target genes, and it regulates the expression of various genes involved in bile acid, lipid, and glucose metabolism (Wang et al., 1999) . FXR plays a role in the induction of genes encoding for proteins involved in xenobiotic metabolism and detoxification (Urquhart et al., 2007; Lee et al., 2010a) . Bile acids are synthesized from cholesterol by a series of enzymatic reactions in hepatocytes and work as a digestive surfactant, promoting lipid absorption (Lefebvre et al., 2009) . Chenodeoxycholic acid (CDCA), a major component in bile acids, serves as a potent ligand of FXR and exerts a hepatoprotective effect (Makishima et al., 1999; Parks et al., 1999) .
The CCAAT/enhancer binding proteins (C/EBPs) belong to the basic region/leucine zipper class transcription factors. In particular, C/EBP␤ is associated with the differentiation of certain cell types, including hepatocytes, adipocytes, macrophages, and granulocytes (Schroeder-Gloeckler et al., 2007) . In the resting state, the unphosphorylated form of C/EBP␤ is mostly located in the cytoplasm. The activation of C/EBP␤ requires phosphorylation at specific residues by cellular kinases, which promotes the process of its nuclear translocation and binding to the C/EBP response element (Buck and Chojkier, 2003) . The N-terminal transactivation domain of C/EBP␤ that binds to the DNA binding element interacts with p300/Creb binding protein and enhances target gene transactivation (Mink et al., 1997) .
Activated C/EBP␤ induces detoxifying enzymes through gene transcription (Kang et al., 2003) . The putative C/EBP binding sites are found in the promoter regions of certain antioxidant genes, including ␥-glutamylcysteine synthetase (GCS) and manganese superoxide dismutase (MnSOD) (Maehara et al., 1999; Kang et al., 2003) . The induction of phase II enzymes and transporters [e.g., UDP-glucuronosyl transferase (UGT) and multidrug resistance protein 2 (Mrp2)] may also depend on C/EBP␤ (Emi et al., 1996; Tanaka et al., 1999) . We previously reported the role of C/EBP␤ activation in the induction of glutathione S-transferase (GST) A2 by a chemopreventive agent (Kang et al., 2003; Ko et al., 2006) . Hence, C/EBP␤ activation is necessary for detoxification, and it may contribute to hepatocyte protection against the challenge of xenobiotics (Kang et al., 2003) .
In view of the role of FXR in xenobiotic metabolism and detoxification, this study investigated the effect of FXR activation by CDCA on C/EBP␤ and the expression of its target detoxifying enzymes. Because FXR promotes hepatocyte survival (Lee et al., 2010a) , we further explored the role of AMP-activated protein kinase (AMPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) activation by FXR in the phosphorylation of C/EBP␤ and its target gene induction. In this study, we report that the activation of FXR by CDCA contributes to the activating phosphorylation of C/EBP␤, which may be mediated by AMPK-dependent ERK1/2 activation.
Primary hepatocytes were isolated from Sprague-Dawley rats as previously described with a minor modification (Kang et al., 2002) . In brief, livers of rats were perfused with Ca 2ϩ -free Hank's balanced saline solution at 37°C for 5 min. Livers were then perfused for 20 min with 0.05% collagenase buffer (collagenase from Clostridium histolyticum, type IV; Sigma-Aldrich) at a perfusion flow rate of 10 ml/min. After perfusion, the livers were minced gently with scissors and suspended with sterilized phosphate-buffered saline (PBS). The cell suspension was filtered through sterilized gauze and centrifuged at 500g for 10 min to separate parenchymal and nonparenchymal cells. The pellet was resuspended in PBS and further centrifuged at 500g for 5 min. The cells were collected from the pellet and cultured on plastic dishes. They were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 50 units/ml penicillin, and 50 g/ml streptomycin at 37°C in humidified atmosphere with 5% CO 2 . The cells were plated at a density of 5 ϫ 10 6 cells/10-cm diameter dish and preincubated for 24 h at 37°C. Preparation of Nuclear Extracts. Nuclear extracts were prepared according to the previously published method (Kang et al., 2003) . In brief, HepG2 cells (1 ϫ 10 7 ) in dishes were washed twice with ice-cold PBS and then scraped from the dishes with 1 ml of PBS and transferred to microfuge tubes. Cells were then centrifuged at 2000g for 5 min. The supernatant was discarded, and the cells were allowed to swell after the addition of 100 l of hypotonic buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.5% Nonidet P-40, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride. The lysates were incubated for 10 min on ice and then centrifuged at 7200g for 5 min at 4°C. Pellets containing crude nuclei were resuspended in 50 l of extraction buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 10 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride, and then were incubated for 30 min on ice. The samples were then centrifuged at 15,800g for 10 min to obtain supernatants containing nuclear fractions. Nuclear fractions were stored at Ϫ70°C until use.
Immunoblot Analyses. SDS-polyacrylamide gel electrophoresis and immunoblot analyses were performed according to previously published procedures (Kang et al., 2003) . Proteins were resolved by gel electrophoresis and electrophoretically transferred to nitrocellulose paper. The nitrocellulose paper was incubated with antibodies overnight and reacted with horseradish peroxidase-conjugated secondary antibody. Bands were developed using an ECL chemiluminescence detection kit (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Equal loading of proteins was verified by immunoblotting for ␤-actin or lamin. Scanning densitometry of the immunoblots was performed with Image Scan and Analysis System (Alpha Innotech Corp., San Leandro, CA). The area of each lane was integrated using the software AlphaEase version 5.5, followed by background subtraction.
Transient Transfection. HepG2 cells were transfected with the plasmidencoding dominant-negative mutant form of AMPK␣ (DN-AMPK␣) or dominant-negative mutant of mitogen-activated protein kinase kinase 1 (DN-MKK1) using FuGENE HD (Roche, Indianapolis, IN). The plasmids encoding for FXR and DN-AMPK␣ were kindly provided by Drs. Bart Staels (Institut Pasteur de Lille, Lille, France) (Claudel et al., 2002) and J. Ha (Kyunghee University, Seoul, Korea), respectively. DN-MKK1 was a gift from Dr. N. G. Ahn (Howard Hughes Medical Institute, University of Colorado, Boulder, CO).
GSTA2 Luciferase Assay. To determine the promoter activities of pGL-1651, pGL-1651-⌬CEBP, and pGL-1651-⌬ARE constructs, the dual-luciferase reporter assay system was used (Promega, Madison, WI), as described previously (Kang et al., 2003) . The pGL-1651 reporter gene construct was generated by ligating the region Ϫ1.65 kb upstream of the transcription start site of the GSTA2 gene to the firefly luciferase reporter gene coding sequences. The mutants of GSTA2 promoter-luciferase plasmid, pGL-1651-⌬C/EBP and pGL-1651-⌬ARE, in which the C/EBP response element (Ϫ905ϳϪ898) and ARE (Ϫ696ϳϪ687) were deleted and replaced with 5Ј-CTCGAG-3Ј, respectively, were constructed as described previously (Kang et al., 2003; Park et al., 2004) .
Real-Time Polymerase Chain Reaction Assays. Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (1 g) was reverse-transcribed using an oligo(dT) 16 primer to obtain cDNA. The cDNA was amplified by polymerase chain reaction (PCR). Realtime PCR was performed with a Light Cycler 1.5 apparatus (Roche, Mann-heim, Germany) using Light Cycler DNA master SYBR Green-I kit according to the manufacturer's instructions. The relative mRNA levels were normalized to those of glyceraldehyde-3-phosphate dehydrogenase using Lightcycler software 4.0 (Roche). After PCR amplification, a melting curve of each amplicon was determined to verify its accuracy. The sequences of the primers used were as follows: human GCLC (sense, 5Ј-TGGCAATGCAGTGGTGGAT-3Ј and antisense, 5Ј-AACACACCTTCCTTCCCATTGA-3Ј); human GCLM (sense, 5Ј-GATCCAAAAGAACTGCTTTCTGAAG-3Ј and antisense, 5Ј-CCTC-TACTTTTCACAATGACCGAAT-3Ј); human MnSOD (sense, 5Ј-CGACCTGC-CCTACGACTACG-3Ј and antisense, 5Ј-TGACCACCACCATTGAACTT-3Ј); human FXR (sense, 5Ј-GGAACCATACTCGCAATACA-3Ј and antisense, 5Ј-TCG-CATGTACATATCCATCA-3Ј); and human glyceraldehyde-3-phosphate dehydrogenase (sense, 5Ј-GAAGATGGTGATGGGATTTC-3Ј and antisense, 5Ј-GAAGGT-GAAGGTCGGAGTC-3Ј).
Animal Experiments. The experiments using animals were conducted under the guidelines of the Institutional Animal Care and Use Committee at Seoul National University. Male ICR mice at 6 weeks of age (25-30 g) were purchased from Orient (Osan, Korea) and housed under filtered pathogen-free air, with commercial chow (Purina, Korea) water ad libitum, at a temperature between 20 and 23°C, with 12-h light/dark cycles and relative humidity of 50%. Mice were treated with CDCA (30 mg/kg i.p., as dissolved in dimethyl sulfoxide) or vehicle once daily for 3 days. Six hours after administration of CDCA, liver samples were excised.
Data Analyses. One-way analysis of variance procedures were used to assess significant differences among treatment groups. For each significant treatment effect, the Newman-Keuls test was used to compare multiple group means.
Results

C/EBP␤-LAP Activation by FXR Agonists.
To determine whether activation of FXR affects the expression of C/EBP isoforms, we first examined the effects of CDCA on C/EBP␣, C/EBP␤-LAP, C/EBP␤-liver-enriched inhibitory protein (C/EBP␤-LIP), and C/EBP␦ levels. Treatment of HepG2 cells with 100 M CDCA increased the levels of C/EBP␤-LAP1/2 in a time-dependent manner (Fig. 1A) ; C/EBP␤-LAP expression levels were significantly increased 6 h after treatment with a maximal increase being noted at 12 h (Fig. 1A) . C/EBP␤-LIP, a form expressed by alternative translation from C/EBP␤ mRNA, dimerizes with C/EBP␤-LAP, and this complex functions as a dominant-negative transcription factor (Descombes and Schibler, 1991; Luedde et al., 2004) . Moreover, the LAP/LIP ratio is important for the transcriptional regulation of the C/EBP␤ target genes (Descombes and Schibler, 1991) . CDCA treatment increased the C/EBP␤-LIP level slightly (e.g., ϳ1.4-fold at 24 h), whereas it increased C/EBP␤-LAP level to a much greater extent (ϳ4-fold) (Fig. 1A) . So, the ratio of LAP to LIP was significantly increased, beginning at 6 h after CDCA treatment, and reached the maximum at 12 h (Fig. 1A, inset) .
The protein levels of other C/EBP isoforms, C/EBP␣ and C/EBP␦, were minimally changed, which suggests the specific effect of CDCA on C/EBP␤ (Fig. 1A) . We next examined the concentration-response FIG. 1. C/EBP␤ activation by CDCA. A, the time course effect of CDCA on the expression of C/EBP isoforms. The isoforms of C/EBP were immunoblotted on the lysates of HepG2 cells treated with 100 M CDCA for the indicated times. Inset shows the ratio of C/EBP␤-LAP to LIP. B, the concentration-response effect of CDCA on C/EBP␤ expression. Cells were treated with CDCA for 12 h. C, increase in the nuclear C/EBP␤-LAP level by CDCA. Nuclear fractions were prepared from cells treated with 100 M CDCA for the indicated time periods (left) and those treated with CDCA for 6 h (right). Immunoblotting for lamin verified equal loading of the nuclear proteins. D, luciferase reporter activity. Induction of luciferase activity by CDCA in HepG2 cells transfected with pGL-1651 that contains the C/EBP response element of the GSTA2 promoter. Luciferase reporter assays were performed on the lysates of HepG2 cells that had been transfected with pGL-1651 or pGL-1651-⌬C/EBP␤ and exposed to vehicle or 100 M CDCA for 12 h. For A-C, the relative C/EBP protein levels were assessed by scanning densitometry of the immunoblots. The level of C/EBP was normalized to that of ␤-actin or lamin. The ratio of C/EBP␤-LAP to LIP was obtained from scanning densitometry of the bands. The data represent the means Ϯ S.E. of at least three separate experiments (significant compared with control, ‫,ء‬ p Ͻ 0.05 or ‫,ءء‬ p Ͻ 0.01; N.S., not significant).
effect of CDCA on the expression of C/EBP␤; treatment of CDCA at 50 M or higher for 12 h increased the levels of C/EBP␤ (Fig. 1B) .
In the resting state, C/EBP␤ is largely present in the cytoplasm as an unphosphorylated form. After activating phosphorylation, C/EBP␤ is translocated into the nucleus and is capable of binding to its cognate DNA sequence (Buck and Chojkier, 2003) . Next, we measured the levels of nuclear C/EBP␤. As expected, treatment with 50 or 100 M CDCA notably elevated nuclear C/EBP␤ content (Fig. 1C) . In the subsequent experiments, we used 100 M CDCA to explore target gene transcription and the associated signaling pathway. To further assess the functional role of C/EBP␤ activation by CDCA for target gene induction, reporter gene assays were performed using pGL-1651 plasmid that has the luciferase gene downstream of the Ϫ1.65-kb GSTA2 promoter region containing the C/EBP response element (C/ EBP-RE). Treatment of pGL-1651-transfected cells with CDCA for 12 h resulted in a 3-fold increase in luciferase activity. CDCA treatment failed to increase luciferase activity from pGL-1651-⌬CEBP, a reporter with the C/EBP-RE deleted (Fig. 1D) , confirming that the induction of the reporter gene results from increased binding of C/EBP␤ to the gene promoter.
To verify the functional role of FXR in C/EBP␤ activation, we further determined the effect of GW4064, a synthetic FXR ligand, on C/EBP␤ levels. GW4064 treatment (5 M) caused the induction of C/EBP␤-LAP1/2 notably from 6 h (at least) to 24 h, and the maximal increase was noted at 12 h ( Fig. 2A ). GW4064 at 3 or 5 M induced C/EBP␤-LAP1/2 (Fig. 2B) . Consistently, it also promoted the nuclear accumulation of C/EBP␤ (Fig. 2C) .
ERK1/2-Dependent C/EBP␤ Phosphorylation by CDCA. Kinases including Ras-ERK-p90 ribosomal S6 kinase (p90RSK), calcium/calmodulin-dependent protein kinase, protein kinase C, and protein kinase A activate C/EBP␤ through phosphorylation (Wegner et al., 1992; Trautwein et al., 1994) . Bile acids stimulate the Ras/Raf-1/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1/ERK pathway (Lee et al., 2010b) . Given the regulatory role of ERK1/2 in C/EBP␤ phosphorylation and the known effect of bile acids on ERK1/2 activation (Lee et al., 2010b) , we assessed the phosphorylation of C/EBP␤ and ERK1/2 in cells treated with CDCA. Immunoblot analyses showed that CDCA treatment gradually increased the phosphorylation of C/EBP␤ at Thr residue (Thr235 residue is phosphorylated by ERK in human; Nakajima et al., 1993; Lee and Kim, 2006) in a time-dependent manner (Fig. 3A) . The levels of phosphorylated C/EBP␤ peaked at 12 or 24 h after CDCA treatment. Total C/EBP␤ content was also increased by CDCA because the activated form of C/EBP␤ transcriptionally induces C/EBP␤ through its binding to the UF1 and UF2 sites in the gene promoter region (Chang et al., 1995) . Thus, the ratio of phospho-C/EBP␤ to total C/EBP␤ was increased at early times after CDCA treatment (i.e., 1-6 h) but not at later times due to the increase in total C/EBP␤ level (Fig. 3A, inset) . CDCA treatment enhanced the phosphorylation of ERK1/2 (Fig. 3B) . The strong increase in phospho-C/EBP␤ level at later times may not only be due to the increase in total C/EBP␤ but also to the persistent activation of ERK1/2. To determine whether ERK1/2 activation affects C/EBP␤ phosphorylation, we monitored the effects of DN-MKK1 and a chemical inhibitor, which inhibit the MEK1/2 necessary for ERK1/2 phosphorylation, on the phosphorylation of C/EBP␤ by CDCA. As expected, either DN-MKK1 transfection or U0126 treatment (an MEK1/2 inhibitor) (Duncia et al., 1998) inhibited the ability of CDCA to promote phosphorylation of C/EBP␤ (Fig. 3C) .
AMPK Activation That Leads to ERK1/2 Phosphorylation. AMPK serves as a key regulator of cell survival or death in response to pathological stress (e.g., endoplasmic reticulum stress, oxidative stress, osmotic stress, and hypoxia) and is activated to reserve energy content in cells (Shaw et al., 2004) . AMPK activation is involved in the induction of metabolizing enzymes (Rencurel et al., 2006) . As an effort to identify the upstream regulator of ERK1/2, we examined the effect of CDCA on AMPK and the role of AMPK in ERK1/2 phosphorylation. CDCA treatment increased AMPK phosphorylation, as shown by increase in the phosphorylation of AMPK␣ and its substrate ACC (Fig. 4A) . Moreover, the extent of ERK1/2 phosphorylation FIG. 2. C/EBP␤ activation by GW4064. A, the time course effect of GW4064 on the expression of C/EBP␤. C/EBP␤ levels were determined on the lysates of HepG2 cells treated with 5 M GW4064. B, the concentration-response effect of GW4064 on C/EBP␤ expression. Cells were treated with GW4064 for 12 h. C, increase in the level of nuclear C/EBP␤ by GW4064. C/EBP␤ levels were measured in the nuclear fractions of HepG2 cells treated with GW4064 for 6 h. Immunoblotting for lamin verified equal loading of the nuclear proteins. For A-C, the relative C/EBP␤-LAP protein levels were assessed by scanning densitometry of the immunoblots. The level of C/EBP-LAP was normalized to that of ␤-actin or lamin. The data represent the means Ϯ S.E. of at least three separate experiments (significant compared with control, ‫,ء‬ p Ͻ 0.05 or ‫,ءء‬ p Ͻ 0.01).
elicited by CDCA was attenuated by DN-AMPK␣ transfection or compound C treatment (a chemical inhibitor of AMPK) (Machrouhi et al., 2010) (Fig. 4B) , suggesting that AMPK activation by CDCA may be involved in the ERK1/2 phosphorylation. Consistently, inhibition of AMPK activity reversed the phosphorylation of C/EBP␤ by CDCA (Fig. 4C) , indicating that the activation of AMPK by CDCA facilitates C/EBP␤ phosphorylation via ERK1/2 activation.
To verify the role of AMPK in the activation of C/EBP␤, we determined the effect of AICAR (a chemical activator of AMPK) on C/EBP␤ and ERK1/2 phosphorylation. As expected, treatment of HepG2 cells with AICAR (1 mM, 6 h) enhanced the phosphorylation of both C/EBP␤ and ERK1/2 (Fig. 4D) . Consistent with the results in HepG2 cells, CDCA treatment promoted the phosphorylation of AMPK␣ and ERK1/2 in rat primary hepatocytes and increased C/EBP␤ phosphorylation at Thr (Thr189 residue is phosphorylated by ERK in rats; Nakajima et al., 1993; Lee and Kim, 2006) (Fig. 4E) . All of these results provide strong evidence that CDCA has the ability to activate AMPK, which may lead to the phosphorylation of ERK1/2 and ERK1/2-dependent phosphorylation of C/EBP␤.
C/EBP␤ Phosphorylation by AMPK-ERK1/2 Pathway Downstream of FXR.
In an effort to clarify the role of FXR in the activation of the AMPK-ERK1/2 pathway responsible for C/EBP␤ phosphorylation, we assessed whether the effect of CDCA on the AMPK-ERK1/2 axis was altered by modulations of FXR activity. We observed that knockdown of FXR attenuated the increases in the phosphorylation of AMPK␣ and ERK1/2 by CDCA (Fig. 5A, left) .
The phosphorylation of C/EBP␤ at Thr235 was also inhibited. Decreased levels of FXR protein and mRNA verified the knockdown effect (Fig. 5A, right) . Consistently, enforced expression of FXR increased the phosphorylation of AMPK␣, ACC, ERK1/2, and C/EBP␤ (Fig. 5B, left) . FXR overexpression was confirmed by marked increases in FXR protein and mRNA content (Fig. 5B, right) . Likewise, GW4064 treatment enhanced the phosphorylation of AMPK␣, ACC, ERK1/2, and C/EBP␤, which was inhibited by FXR knockdown (Fig. 5C ). The total protein levels of AMPK␣ and ERK1/2 were not affected by FXR knockdown or overexpression (Supplemental Fig. 1 ). These results indicate that the activation of FXR by its ligand contributes to the phosphorylation of C/EBP␤ through the pathway involving AMPK-dependent ERK1/2 activation.
Effects of FXR Agonists on the Induction of Detoxifying Enzymes. Oxidative stress promotes the progression of various diseases by altering intracellular redox homeostasis, thereby sometimes causing cell death when the stress persists or exceeds the range of cellular antioxidative capacity (Shaw et al., 2004) . In a continuing effort to define the functional outcome of CDCA treatment in terms of antioxidant capacity, we measured the effect of CDCA treatment on the levels of glutamate-cysteine ligase catalytic subunit, glutamate-cysteine ligase modifier subunit, and MnSOD transcripts from the genes containing the C/EBP-RE (Maehara et al., 1999; Yang et al., 2001) . As expected, CDCA treatment significantly increased all of the transcript levels in a time-dependent manner (Fig. 6A) . GW4064 had similar effects. Immunoblot analysis verified the induction of ␥- GCS   FIG. 3 . The role of ERK1/2 in C/EBP␤ phosphorylation by CDCA. A, the time course effect of CDCA on C/EBP␤ phosphorylation. Phosphorylated C/EBP␤ levels were assessed in the lysates of HepG2 cells treated with 100 M CDCA. The relative protein levels were measured by scanning densitometry of the immunoblots (bottom). The level of p-C/EBP␤ was normalized to that of ␤-actin. The inset shows the relative ratio of p-C/EBP␤ to total C/EBP␤. B, the time course effect of CDCA (100 M) on ERK1/2 phosphorylation in HepG2 cells. C, the role of ERK1/2 in C/EBP␤ phosphorylation by CDCA. HepG2 cells that had been transfected with DN-MKK1 for 6 h were treated with 100 M CDCA for 12 h (left). Cells were exposed to CDCA for 12 h after U0126 treatment (10 M for 1 h) (right). The relative protein levels were measured by scanning densitometry of the immunoblots. The protein level was normalized to that of ␤-actin or ERK1/2. The data represent the means Ϯ S.E. of at least three separate experiments (significant compared with control, ‫,ء‬ p Ͻ 0.05 or ‫,ءء‬ p Ͻ 0.01; significant compared with CDCA treatment, # , p Ͻ 0.05).
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Finally, we determined the effect of CDCA on C/EBP␤ in vivo. Administration of CDCA to mice (30 mg/kg i.p. per day for 3 days) notably increased phosphorylated and total C/EBP␤ levels in the liver (Fig. 6C) . Moreover, CDCA treatment induced UGT1A, HO-1, GSTA2, and Mrp2 (Fig. 6D ), protein products from the genes containing C/EBP-RE. Taken together, these data suggest that CDCA induces antioxidant and xenobiotic-metabolizing enzymes by activating C/EBP␤ through the AMPK-dependent ERK1/2 pathway downstream of FXR, which may contribute to maintaining overall homeostasis in hepatocytes.
Discussion
The liver plays a major role in eliminating xenobiotics from the body, and this process is accomplished by a series of metabolizing enzymes. Detoxifying enzymes include phase II enzymes and transporters: phase II enzymes function to protect the body from environmental insults by conjugating xenobiotics with endogenous compounds, and transporters in the liver mediate the efflux of transformed metabolites across the hepatocyte canalicular membrane to the bile. Detoxifying enzymes increase the capacity of antioxidant defense as well as metabolic detoxification, which contributes to the maintenance of redox homeostasis and cell viability. Transactivation of the genes encoding for phase II enzymes and transporters are coordinately regulated by transcription factors in response to external stimuli (Emi et al., 1996) .
In animal models, feeding diets containing bile acids enhanced the expression of phase II enzymes and transporters (Zollner et al., 2003) , suggesting that bile acids modulate the gene expression. It is also likely that bile acids have the ability to protect the liver from oxidative stimuli by inducing an antioxidant defense system. CDCA, a major component in bile acids, exerts a hepatoprotective effect. C/EBP␤ is a key transcription factor necessary for the expression of genes involved in maintaining normal liver physiology (Rastegar et al., 2000) . In this study, we found for the first time that CDCA activates C/EBP␤ in hepatocytes. This finding, together with the results of luciferase reporter gene assay, supports the role of C/EBP␤ activation by CDCA in the transcriptional induction of detoxifying enzymes. The necessity of C/EBP␤ binding to the C/EBP-RE in inducing the target genes was strengthened by our experiment using a mutant promoter lacking the C/EBP binding site.
Other isoforms of C/EBP may also be involved in the expression of liver-specific genes. In untreated cells, C/EBP␣ may be part of the proteins that bind to the C/EBP binding site (Lin et al., 1993) . Thus, the biological effect evoked by C/EBP on the transcription of liverspecific genes might depend on the relative activities of C/EBP␣ and C/EBP␤. It is also possible that an active form of C/EBP␤ competes with C/EBP␣ for the C/EBP binding site. In the present study, we observed that CDCA treatment did not affect the expression levels of C/EBP␣ and C/EBP␦ (Fig. 1A) . Hence, it is apparent that CDCA FIG. 4 . AMPK activation by CDCA and its regulation of ERK1/2. A, AMPK activation by CDCA. Immunoblot analyses were performed on the lysates of HepG2 cells treated with 100 M CDCA for the indicated times (left). B, reversal of CDCA-induced ERK1/2 phosphorylation by AMPK inhibition. HepG2 cells that had been transfected with DN-AMPK␣ for 6 h were treated with 100 M CDCA for 12 h (left). Cells were exposed to CDCA for 12 h after compound C treatment (5 M for 1 h) (right). C, reversal of CDCA-induced C/EBP␤ phosphorylation by AMPK inhibition. HepG2 cells were treated as described in B. D, the phosphorylation of C/EBP␤ and ERK1/2 by AICAR. Immunoblotting was performed on the lysates of HepG2 cells treated with AICAR (1 mM for 6 h). E, the activation of AMPK, ERK1/2, and C/EBP␤ by CDCA in rat primary hepatocytes. Immunoblot analyses were performed on the lysates of primary hepatocytes treated with 100 M CDCA. Values indicate fold changes. The relative protein levels were measured by scanning densitometry of the immunoblots. The protein level was normalized to that of ␤-actin. The data represent the means Ϯ S.E. of at least three separate experiments (significant compared with control, ‫,ء‬ p Ͻ 0.05 or ‫,ءء‬ p Ͻ 0.01; significant compared with CDCA, # , p Ͻ 0.05).
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FXR is expressed in major organs including liver, intestine, kidney, and adrenal gland (Wang et al., 1999) . Upon bile acid binding, FXR positively regulates a series of genes responsible for maintaining normal liver physiology, thus protecting the hepatocyte from environmental insults (Huang et al., 2006; Lee et al., 2010a) . In particular, CDCA is a major bile acid constituent that exerts a hepatoprotective effect by activating FXR. The importance of FXR activation in C/EBP␤-mediated detoxifying enzyme induction was further supported by our finding that GW4064 also activated C/EBP␤ and induced the genes encoding antioxidant enzymes. All of our results lend support to the contention that the activation of C/EBP␤ by FXR accounts, at least in part, for the molecular basis of target enzyme induction, which explains the cytoprotective and adaptive response elicited by bile acid. AMPK monitors energy status by responding to changes in the cellular AMP/ATP ratio, which functions as an energy-sensing molecule (Shaw et al., 2004) . AMPK activation exerts an antiapoptotic effect, whereas its abrogation increases cell injury and apoptosis (Ido et al., 2002) . Another important finding of this study is the identification of FXR as a mediator that activates AMPK. Our data demonstrate the role of FXR-dependent AMPK activation in promoting C/EBP␤ phosphorylation by CDCA. It seems that FXR gives a signal to activate AMPK through the LKB1-dependent pathway by regulating a specific microRNA expression (C. G. Lee, Y. W. Kim, and S. G. Kim, unpublished data) . Considering the importance of AMPK and C/EBP␤ in hepatocyte survival, it is predicted that AMPK-dependent C/EBP␤ activation may contribute to the ability of CDCA to maintain hepatocyte viability. This concept is in line with the previous findings that AMPK activation induces HO-1 via peroxisome proliferatoractivated receptor ␣ activation in the liver and protects cells from oxidative stress (Shin and Kim, 2009; Lin et al., 2010) .
The receptor-activated signaling pathways regulate the phosphorylation of C/EBP␤ in its activation domains. Several kinases including Ras-ERK-p90RSK, calcium/calmodulin-dependent protein kinase, protein kinase C, and protein kinase A are responsible for the phosphorylation of C/EBP␤ (Wegner et al., 1992; Trautwein et al., 1994) . It has been shown that deoxycholic acid treatment activated the MEK1/ERK pathway (Lee et al., 2010b) . In addition, ERK1/2 is responsible for the phosphorylation of the human C/EBP␤ form at Thr235 residue (Nakajima et al., 1993; Lee and Kim, 2006) . Our additional results showed that CDCA treatment enhanced the phosphorylation of c-jun amino-terminal-kinase (JNK) and p38 kinase (Supplemental Fig. 2A) . However, only U0126 (an MEK1/2 inhibitor), but not 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580) (a p38 kinase inhibitor) or 1, 9-pyrazoloanthrone (SP600125) (a JNK inhibitor), inhibited the phosphorylation of C/EBP␤ by CDCA (Supplemental Fig. 2B ), supporting the contention that ERK1/2 is predominantly responsible for the phosphorylation of C/EBP␤ among the mitogen-activated protein kinases.
The results of the present study also confirmed the ability of AMPK to regulate ERK1/2, which is consistent with the observation that AICAR activated Raf-1/MEK/ERK/p90RSK signaling cascade (Wang et al., 2007) . Our results that FXR knockdown attenuated increases in the phosphorylation of ERK1/2 and C/EBP␤ by CDCA, whereas enforced expression of FXR increased them, provided com- pelling evidence that FXR plays a role in activating C/EBP␤ through ERK1/2. Overall, our finding that AMPK inhibition reversed CDCAinduced ERK1/2 and C/EBP␤ phosphorylation supports the conclusion that AMPK-mediated ERK1/2 activation downstream of FXR contributes to CDCA-induced C/EBP␤ phosphorylation, which leads to the transcriptional induction of C/EBP␤ target genes.
CDCA treatment also activated nuclear factor erythroid-2-related factor 2 (Nrf2) in HepG2 cells (Supplemental Fig. 3, A and B) , as further supported by the result of antioxidant response element reporter assay (Supplemental Fig. 3C ). Our data are in agreement with the observation that CDCA treatment activated Nrf2 and induced its target genes in the liver and intestinal cells (Tan et al., 2007) . Ursodeoxycholic acid, another bile acid, has been used in clinical studies to treat liver diseases including primary biliary cirrhosis, and a large part of its beneficial aspect may be attributable to its property of Nrf2 activation (Okada et al., 2008; Kawata et al., 2010) . Hence, it is presumed that an enhanceosome complex containing C/EBP␤ and Nrf2 may work together in inducing target genes by CDCA.
In summary, the results of the present study demonstrate that CDCA activates C/EBP␤ by phosphorylating C/EBP␤ through the AMPK-ERK1/2 pathway downstream of FXR activation (Fig. 6E) , contributing to the cooperative assembly of an activated transcription complex at the target gene promoters. Consequently, activation of C/EBP␤ by CDCA may be necessary for the induction of detoxifying enzymes.
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Supplemental Materials
Antibody recognizing nuclear factor erythroid-2-related factor 2 (Nrf2) were provided by Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-JNK, anti-phospho-p38 kinase, and phospho-C/EBP antibodies were purchased from Cell Signaling Technology (Beverly, MA).
Anti--actin antibody was provided from Sigma (St. Louis, MO). SB203580 was supplied from Sigma Chemical (St. Louis, MO), whereas SP600125 (JNKI, a JNK inhibitor) was provided from Calbiochem (San Diego, California).
Supplemental Figures
Supplemental Fig. 1 
